eli lilly and company news

Eli Lilly’s stock falls

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

MarketWatch · 17m

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

Business Insider · 20h

Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an

Seeking Alpha · 3d

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Eli Lilly acquires cancer program from Scorpion Therapeutics

Reuters · 1d

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

Ibj.com · 21h

Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

BioPharma Dive · 23h

Lilly pads cancer drug pipeline with Scorpion deal

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.

FierceBiotech1d

JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

STAT4d

Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund

Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...

Yahoo Finance1d

Eli Lilly and Company (LLY)

As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK). Maurits Pot, CEO of Tema ETFs, joins Market Domination to give his predictions for ...

Hosted on MSN1d

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

Eli Lilly and Company (NYSE:LLY) Shares Acquired by Czech National Bank

Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...

Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly

Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the ...

4don MSN

Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Eli Lilly’s stock falls

Eli Lilly acquires cancer program from Scorpion Therapeutics

Related topics